Benzamide Antibacterial Agents for Drug-Resistant Infections
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The rapid development of drug-resistant bacterial strains has rendered many antibiotics ineffective, leading to millions of infections and thousands of deaths annually, with treatment costs exceeding $20 billion per year.
Innovation Solution
Development of benzamide antibacterial agents with specific functional groups and substituents, including compounds with formulas (I) and their pharmaceutically acceptable salts, which can be administered alone or in combination with other compounds, conjugates, or as nanoparticles, to enhance solubility and targeting, and used in prodrugs for targeted delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional antibiotics are used to treat bacterial infections, then initial treatment effectiveness is achieved, but bacterial resistance develops rendering the antibiotics ineffective
Solution Approach 1:
The patent employs combination therapy by dividing the treatment into multiple components: a first compound (e.g., vancomycin or other glycopeptide) and a second compound (benzamide derivative). This segmentation prevents any single bacterial mechanism from overcoming all treatments simultaneously, thereby extending effective treatment duration and preventing resistance development.
Solution Approach 2:
The patent creates a composite treatment regimen combining compounds with different mechanisms of action. The first compound targets cell wall synthesis (glycopeptide binding to D-Ala-D-Ala), while the second compound (benzamide) targets alternative pathways or structures. This composite approach ensures that resistance to one component does not confer resistance to the other, maintaining long-term effectiveness.
2Adaptability or versatility
If new antibacterial compounds are developed to overcome resistance, then treatment options are expanded, but development and treatment costs increase
Solution Approach 1:
The benzamide compounds described in the patent are designed with broad-spectrum activity against multiple drug-resistant bacterial strains (MRSA, VRE, VRSA). This multi-functionality allows a single compound class to address various resistance scenarios, reducing the need for multiple specialized drugs and thereby controlling overall treatment costs while expanding adaptability.
Solution Approach 2:
The patent modifies the molecular structure of conventional antibiotics by introducing benzamide substituents at specific positions (e.g., position 2 of the sugar moiety). These parameter changes in molecular structure create new compounds with enhanced activity against resistant strains, providing cost-effective alternatives to entirely new antibiotic classes while maintaining structural relationships to known drugs.
3Reliability
If combination therapy is used to prevent resistance, then treatment effectiveness is maintained, but device and protocol complexity increases
Solution Approach 1:
The patent merges two compounds with different mechanisms of action into a single treatment protocol. The first compound (glycopeptide) and second compound (benzamide derivative) are administered together or in sequence to achieve synergistic effects. This combining approach maintains simplicity by integrating resistance prevention into the primary treatment regimen rather than requiring separate adjunctive therapies.
Data Source
AI summary
The present invention generally relates to compounds as a new antibiotic to treat various infections, including infections caused by methicillin-resistant Staphylococcus aureus, vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis and Clostridioides difficile. Pharmaceutical compositions and methods for treating those diseases are within the scope of this invention.